LEADER 01793oam  2200457   450 
001 9910713514803321
005 20220415144832.0
024 8 $a29-412
035   $a(CKB)5470000002502519
035   $a(OCoLC)1156626967
035   $a(OCoLC)995470000002502519
035   $a(EXLCZ)995470000002502519
100   $a20200603d2020      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPerspectives on the 340B Drug Pricing Program $ehearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining perspectives on the 340B drug discount program, March 15, 2018
210  1$aWashington :$cU.S. Government Publishing Office,$d2020.
215   $a1 online resource (iii, 70 pages)
225 1 $aS. hrg. ;$v115-810
300   $aAccess ID (govinfo): CHRG-115shrg29412.
320   $aIncludes bibliographical references.
517   $aPerspectives on the 340B Drug Pricing Program 
606   $aPrescription pricing$xGovernment policy$zUnited States
606   $aDrugs$xPrices$xGovernment policy$zUnited States
606   $aPoor$xPharmaceutical assistance$zUnited States
606   $aOlder people$xPharmaceutical assistance$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aPrescription pricing$xGovernment policy
615  0$aDrugs$xPrices$xGovernment policy
615  0$aPoor$xPharmaceutical assistance
615  0$aOlder people$xPharmaceutical assistance
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910713514803321
996   $aPerspectives on the 340B Drug Pricing Program$93474770
997   $aUNINA